Clinical trial

A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors

NCT03125746

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2017-06-12

PhasePHASE1

Study timeline

Study start (actual)2017-06-12Date precision: day

Registry last updated2021-01-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Breast Cancerunresolved

Interventions

LXI-15029DRUG

LXI-15029+ExemestaneDRUG

Sponsors & collaborators

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.lead sponsor

Mapped research locations

BeijingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03125746 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.